3 citations · 6 across the 4 of their papers we have counts for
7 papers
Joint modelling of longitudinal and time-to-event data applied to group sequential clinical trials
Abigail J. Burdon, Lisa V. Hampson, Christopher Jennison
Often in Phase 3 clinical trials measuring a long-term time-to-event endpoint, such as overall survival or progression-free survival, investigators also collect repeated measures o…
Combining the target trial and estimand frameworks to define the causal estimand: an application using real-world data to contextualize a single-arm trial
Lisa V Hampson, Jufen Chu, Aiesha Zia +5
Single-arm trials (SATs) may be used to support regulatory submissions in settings where there is a high unmet medical need and highly promising early efficacy data undermine the e…
Eliciting judgements about dependent quantities of interest: The SHELF extension and copula methods illustrated using an asthma case study
Björn Holzhauer, Lisa V. Hampson, John Paul Gosling +8
Pharmaceutical companies regularly need to make decisions about drug development programs based on the limited knowledge from early stage clinical trials. In this situation, elicit…
Improving the assessment of the probability of success in late stage drug development
Lisa V Hampson, Björn Bornkamp, Björn Holzhauer +6
There are several steps to confirming the safety and efficacy of a new medicine. A sequence of trials, each with its own objectives, is usually required. Quantitative risk metrics…
Efficient adaptive designs for clinical trials of interventions for COVID-19
Nigel Stallard, Lisa Hampson, Norbert Benda +14
The COVID-19 pandemic has led to an unprecedented response in terms of clinical research activity. An important part of this research has been focused on randomized controlled clin…
A Bayesian hierarchical model for bridging across patient subgroups in phase I clinical trials with animal data
Haiyan Zheng, Lisa V. Hampson, Thomas Jaki
Incorporating preclinical animal data, which can be regarded as a special kind of historical data, into phase I clinical trials can improve decision making when very little about h…